logo
ProjectOngoing

Mobile Artificial Intelligence Solution for Diabetes Adaptive Care

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

The MELISSA project aims to provide a clinically validated, effective, trustworthy, and cost-efficient artificial intelligence (AI)-based digital diabetes management solution to support both health care providers (HCPs) and insulin-treated patients with diabetes (PwD) in their daily routine with personalised treatment and care recommendations. The solution is independent of the used glucose monito

Status
Under Construction
Sector
Residential, Commercial
Location
Netherlands, Greece, Denmark, Spain, Germany, United States
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Mobile Artificial Intelligence Solution for Diabetes Adaptive Care

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Mobile Artificial Intelligence Solution for Diabetes Adaptive Care” is an infrastructure initiative in the Residential sector, located in Netherlands, Greece, Denmark, Spain, Germany, United States. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The MELISSA project aims to provide a clinically validated, effective, trustworthy, and cost-efficient artificial intelligence (AI)-based digital diabetes management solution to support both health care providers (HCPs) and insulin-treated patients with diabetes (PwD) in their daily routine with personalised treatment and care recommendations. The solution is independent of the used glucose monitoring devices and is based on the combined use of already prototyped advanced AI-approaches and innovative tools for quantification of lifestyle and behavioural factors, taking into consideration sex/gender aspects, age, and socio-economic parameters related to the development of diabetes. More specifically, core element of the project is the daily insulin treatment adjustment to ensure glucose control using an already introduced self-learning approach based on reinforcement learning. The approach is data-driven, real-time and of low computational cost and allows daily adjustment of the insulin infusion profile, on the basis of the fluctuations in the patient?s glucose. The approach takes into consideration patients treatment-related (glucose, insulin, and carbohydrate intake) and conceptual information and during the project will be further extended and optimized to include additional lifestyle and behavioural parameters. Furthermore, tools for assessing the risk of short- and long-term complications will assist HCPs in reaching better decisions on adjustments to the treatment schemes. To meet the objectives the consortium brings together partners active in the fields of diabetes (PwD and HCPs), diabetes technology, AI, behavioral sciences, ethics in AI, regulatory affairs, healthcare economics and clinical trials to further co-create, clinically develop, optimize, and clinically validate an AI-based solution for more effective and cost-efficient diabetes management through personalised treatment and care.

Location

Country

Netherlands, Greece, Denmark, Spain, Germany, United States

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Residential, Commercial

Article published date

2025-12-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project